المؤلفون: A. Isyangulova Z., R. Khasanov Sh., R. Enikeev F., А. Исянгулова З., Р. Хасанов Ш., Р. Еникеев Ф.

المصدر: Malignant tumours; Том 9, № 4 (2019); 49-58 ; Злокачественные опухоли; Том 9, № 4 (2019); 49-58 ; 2587-6813 ; 2224-5057

مصطلحات موضوعية: neuroendocrine tumor, targeted therapy, carcinoid, pancreatic cancer, gastrointestinal cancer, нейроэндокринная опухоль, таргетная терапия, карциноид, рак поджелудочной железы, рак желудочно-кишечного тракта

وصف الملف: application/pdf

العلاقة: https://www.malignanttumors.org/jour/article/view/685/481Test; Diagnosis and management of gastrointestinal neuroendocrine tumors: an evidence-based Canadian consensus / Singh S, Asa SL, Dey C, Kennecke H, Laidley D, Law C. et al. // Cancer Treat. 2016. V. 47. P. 32 – 45.; One hundred years after «carcinoid»: epidemiology of and prognostiс factors for neuroendocrine tumors in 35,825 cases in the United States / Yao J., Hassan M., Phan A., Dagohoy C., Leary C., Mares JE. et al. // Clin. Oncol. 2008. V. 26. N18. P. 3063 – 3072.; Горбунова В. А. Нейроэндокринные опухоли. Общие принципы диагностики и лечения. М.: Кодекс, 2015. 456 с.; UKNETwork for neuroendocrine tumours. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours / Ramage J., Davies A., Ardill J. et al. // Gut. 2005. V. 54. N4. P. 1 – 16.; Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival / Halfdanarson T., Rabe K., Rubin J. et al. // Annals of Oncology. 2008. V. 19. N10. P. 1727 – 1733.; Modlin I. M., Lye K. D., Kidd M. A. 5‑decade analysis of 13,715 carcinoid tumors // Cancer. 2003. V. 97. P. 934 – 959.; Lepage C, Rachet B, Coleman MP. Survival from malignant digestive endocrine tumors in England and Wales: a population-based study // Gastroenterology. 2007. V. 132. P. 899 – 904.; Population-based study of islet cell carcinoma / Yao J., Eisner M., Leary C. et al. // Ann Surg Oncol. 2007. V. 14. P. 492 – 500.; Moertel C., Kvols L., O’Connell M., Rubin J. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms // Cancer. 1991. V. 68. P. 227 – 232.; Moertel C., Hanley J. Combination chemotherapy trials in metastatic carcinoid tumor and the malignant carcinoid syndrome // Cancer clinical trials. 1979. V. 2. P. 327 – 334.; Практические рекомендации Российского общества клинической онкологии. Лекарственное лечение злокачественных опухолей. Поддерживающая терапия в онкологии / под ред. В. М. Моисеенко. // Злокачественные опухоли. Спецвыпуск. 2019. 776 с.; O’Toole D., Kiaуmanesh R., Caplin M. ENETS 2016 Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Tumors: An Update // Neuroendocrinology. 2016. V. 103. P. 117 – 118.; Susini C, Buscail L. Rationale for the use of somatostatin analogs as antitumor agents // Annals Oncology. 2006. V. 17. N12. P. 1733 – 1742.; Wimmel A., Wiedenmann B., Rosewicz S. Autocrine growth inhibition by transforming growth factor beta-1 (TGFbeta-1) in human neuroendocrine tumour cells // Gut. 2003. V. 52. P. 1308 – 1316.; Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis / von Marschall Z., Scholz A., Cramer T., Schafer G., Schirner M., Oberg K, et al. // Natl Cancer Inst. 2003. V. 95. P. 437 – 448.; Chaudhry A., Papanicolaou V., Oberg K., Heldin C., Funa K. Expression of platelet-derived growth factor and its receptors in neuroendocrine tumors of the digestive system // Cancer Res. 1992. V. 52. P. 1006 – 1012.; Wulbrand U., Remmert G., Zofel P., Wied M., Arnold R., Fehmann H. mRNA expression patterns of insulin-like growth factor system components in human neuroendocrine tumours // Eur J Clin Invest. 2000. V. 30. P. 729 – 739.; Insulin-like growth factor-I is an autocrine regulator of chromogranin A secretion and growth in human neuroendocrine tumor cells / von Wichert G., Jehle P., Hoeflich A., Koschnick S., Dralle H, Wolf E. et al. // Cancer Res. 2000. V. 60. P. 4573 – 4581.; Nilsson O., Wangberg B., Theodorsson E., Skottner A., Ahlman H. Presence of IGF-I in human midgut carcinoid tumours--an autocrine regulator of carcinoid tumour growth? // Int J Cancer. 1992. V. 51. P. 195 – 203.; Zhang H., Yee D. The therapeutic potential of agents targeting the type I insulin-like growth factor receptor // Expert Opin Investig Drugs. 2004. V. 13. P. 1569 – 1577.; Gastrointestinal Neuroendocrine Tumors: Pancreatic Endocrine Tumors / Metz, David C. et al. // Gastroenterology. 2008. V. 135. N5. P. 1469 – 1492.; Wiedmann M., Caca K. Molecularly targeted therapy for gastrointestinal cancer // Curr Cancer Drug Targets. 2005. V. 5. P. 171 – 193.; Smolewski P. Recent developments in targeting the mammalian target of rapamycin (mTOR) kinase pathway // Anticancer Drugs. 2006. V. 17. P. 487 – 494.; Dancey J. Therapeutic targets: MTOR and related pathways // Cancer Biol Ther. 2006. V. 5. P. 1065 – 1073.; EGFR targeting of solid tumors / Rocha-Lima C., Soares H., Raez L. et al. // Cancer Control. 2007. V. 14. P. 295 – 304.; Harari P. Epidermal growth factor receptor inhibition strategies in oncology // Endocr Relat Cancer. 2004. V. 11. P. 689 – 708.; Bjornsti M., Houghton P. The TOR pathway: a target for cancer therapy // Nat Rev Cancer. 2004. V. 4. P. 335 – 348.; BAY 43 – 9006 exhibits broad spectrum oral antitumor activity and targets the RAF / MEK / ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis / Wilhelm S., Carter C., Tang L., Wilkie D., McNabola A., Rong H. et al.// Cancer Res. 2004. V. 64. P. 7099 – 7109.; Interaction between the epidermal growth factor receptor (EGFR) and the vascular endothelial growth factor (VEGF) pathways: a rational approach for multi-target anticancer therapy / Ciardiello F., Troiani T., Bianco R., Orditura M., Morgillo F., Martinelli E. et al. // Annals of Oncology. 2006. V. 17. N 7. P. 109 – 114.; Maione P., Gridelli C., Troiani T., Ciardiello F. Combining targeted therapies and drugs with multiple targets in the treatment of NSCLC// Oncologist. 2006. V. 11. P. 274 – 284.; Burgaud JL, Baserga R. Intracellular transactivation of the insulin-like growth factor I receptor by an epidermal growth factor receptor // Exp Cell Res. 1996. V. 223. P. 412 – 419.; Activation of BAD by therapeutic inhibition of epidermal growth factor receptor and transactivation by insulin-like growth factor receptor / Gilmore A., Valentijn A., Wang P., Ranger A., Bundred N., O’Hare M. et al.//J Biol Chem. 2002. V. 277. P. 27643 – 27650.; Jain R., Duda D., Clark J., Loeffler J. Lessons from phase III clinical trials on anti-VEGF therapy for cancer // Nat Clin Pract Oncol. 2006. V. 3. P. 24 – 40.; Morabito A., De Maio E., Di Maio M., Normanno N., Perrone F. Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions // Oncologist. 2006. V. 11. P. 753 – 764.; Hopfner M., Sutter A., Gerst B., Zeitz M., Scherubl H. A novel approach in the treatment of neuroendocrine gastrointestinal tumours. Targeting the epidermal growth factor receptor by gefitinib (ZD1839) // Br J Cancer. 2003. V. 89. P. 1766 – 1775.; Hopfner M., Baradari V., Huether A., Schofl C., Scherubl H. The insulin-like growth factor receptor 1 is a promising target for novel treatment approaches in neuroendocrine gastrointestinal tumours // Endocr Relat Cancer. 2006. V. 13. P. 135 – 149.; Elevated expression of vascular endothelial growth factor correlates with increased angiogenesis and decreased progression-free survival among patients with low-grade neuroendocrine tumors / Zhang J., Jia Z., Li Q., Wang L., Rashid A, Zhu Z. et al. // Cancer. 2007. V. 109. P. 1478 – 1486.; Pavel M., Hassler G., Baum U., Hahn E., Lohmann T., Schuppan D. Circulating levels of angiogenic cytokines can predict tumour progression and prognosis in neuroendocrine carcinomas // Clin Endocrinol (Oxf). 2005. V. 62. P. 434 – 443.; Carmeliet P., Jain R. Molecular mechanisms and clinical applications of angiogenesis // Nature 473. 2011. P. 298 – 307.; Anti-vascular endothelial growth factor antibody single therapy for pancreatic neuroendocrine carcinoma exhibits a marked tumor growth-inhibitory effect / Kasuya K., Nagakawa Y., Suzuki M., Tanaka H., Ohta H., Itoi T. et al. // Exp Ther Med 2. 2011. P. 1047 – 1052.; Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors / Chan J., Stuart K., Earle C., Clark J., Bhargava P., Miksad R. et al. // J Clin Oncol. 2012. V. 30. P. 2963 – 2968.; Reinacher-Schick, ASCO-update 2015 — highlights of the 51 meeting of the american society of clinical oncology // Lorenzen S., Arnold D., Fottner C., Leichsenring J., Moehler M., Seufferlein T., et al. //ASCO 2015, Z Gastroenterol. 2016. V. 54. N 02. P. 167 – 172.; (2015b) Randomized phase II study of everolimus (E) versus everolimus plus bevacizumab (E+B) in patients (Pts) with locally advanced or metastatic pancreatic neuroendocrine tumors (pNET), CALGB 80701 (Alliance) / Kulke M., Niedzwiecki D., Foster N., Fruth B., Kunz P., Kennecke H. et al.// J Clin Oncol. 2015. V. 33. N 15. P. 4005.; Randomized phase II study of everolimus (E) versus everolimus plus bevacizumab (E+B) in patients (Pts) with locally advanced or metastatic pancreatic neuroendocrine tumors (pNET), CALGB 80701 (Alliance) / Matthew H. Kulke, Donna Niedzwiecki, Nathan R. Foster, Briant Fruth, Pamela L. Kunz, Hagen F. Kennecke et al. // J Clin Oncol. 2015. V. 33. N 15. P. 4005.; Phase III prospective randomized comparison trial of depot octreotide plus interferon alfa-2b versus depot octreotide plus bevacizumab in patients with advanced carcinoid tumors: SWOG S0518 / Yao J., Guthrie K., Moran C. et al. // J Clin Oncol. 2017. doi:10.1200 / JCO. 2016. V. 70. P. 4072; Перспективы использования бевацизумаба при НЭО. Клинический случай / Г. С. Емельянова, Н. Ф. Орел, В. А. Горбунова, А. А. Коломейцева, А. А. Кузнецова, А. Е. Кузьминов и др. // Сибирский онкологический журнал. 2017. Т. 16. № 6. C. 100 – 104.; Bevacizumab plus octreotide and metronomic capecitabine in patients with metastatic well-to-moderately differentiated neuroendocrine tumors: the xelbevoct study / Berruti A., Fazio N., Ferrero A., Brizzi M., Volante M., Nobili E. et al. // BMC Cancer. 2014. V. 14. P. 184.; Bevacizumab plus capecitabine in patients with progressive advanced well-differentiated neuroendocrine tumors of the gastro-intestinal (GI-NETs) tract (BETTER trial) — a phase II non-randomised trial / Mitry E., Walter T., Baudin E., Kurtz J. E., Ruszniewski P., Dominguez-Tinajero S. et al. // Eur J Cancer. 2014. V. 50. N 18. P. 3107 – 3115.; Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma / Helfrich I., Scheffrahn I., Bartling S., Weis J., von Felbert V., Middleton M. et al. // J Exp Med 207. 2010. P. 491 – 503.; Sitohy B., Nagy J., Dvorak H. Anti-VEGF / VEGFR therapy for cancer: Reassessing the target // Cancer Res 72. 2012. P. 1909 – 1914.; Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericytemediated endothelial cell survival mechanisms / Erber R., Thurnher A., Katsen A., Groth G., Kerger H., Hammes H. et al. // FASEB J 18. 2004. P. 338 – 340.; Wilhelm S., Chien D. BAY 43 – 9006: preclinical data // Curr Pharm Des. 2002. V. 8. P. 2255 – 2257.; Role of Raf kinase in cancer: therapeutic potential of targeting the Raf / MEK / ERK signal transduction pathway / Gollob J., Wilhelm S., Carter C., Kelley S. //Semin Oncol. 2006. V. 33. P. 392 – 406.; Sorafenib blocks the RAF / MEK / ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC / PRF / 5 / Liu L., Cao Y., Chen C., Zhang X., McNabola A., Wilkie D. et al. // Cancer Res. 2006. V. 66. P. 11851 – 11858.; Hobday TJ, Rubin J, Holen K. MC044h, a phase II trial of sorafenib in patients with metastatic neuroendocrine tumors (NET): A Phase II Consortium (P2C) study // Clin Oncol. 2007, ASCO Annual Meeting Proceedings Part 1. 2007. V. 25. N 18. P. 4504.; Activity of Sunitinib in Patients With Advanced Neuroendocrine Tumors / Matthew H. Kulke, Heinz-Josef Lenz, Neal J. Meropol et al. // Clin Oncol. 2008. V. 20. P. 3404 – 3410.; Sunitinib malate for the treatment of pancreatic neuroendocrine tumors Raymond E., Dahan L., Raoul J. et al. // N Engl J Med. 2011. V. 364. Р. 501 – 513.; Motzer R., Bukowski R. Targeted therapy for metastatic renal cell carcinoma // Clin Oncol. 2006. V. 24. P. 5601 – 5608.; Kulke M., Bergsland E., Ryan D. A Phase II study to evaluate the safety and efficacy of SU11248 in patients with unresectable neuroendocrine tumors // Proc Am Soc Clin Oncol. 2003. V. 22. P. 958.; A phase two study to evaluate the efficacy and safety of SU11248 in patients (pts) with unresectable neuroendocrine tumors (NET) // Kulke M., Lenz H., Meropol N., Posey J., Ryan D., Picus J. et al. // J Clin Oncol. 2005. V. 23. P. 4008.; Updated results of the phase III trial of sunitinib (SU) versus placebo (PBO) for treatment of advanced pancreatic neuroendocrine tumors (NET) / Raymond E., Niccoli-Sire P., Bang Y. et al. // ASCO Gastrointestinal Cancers Symposium. Book of abstracts. 2010. Abstract 127.; Pietras K., Hanahan D. A multitargeted, metronomic, and maximum-tolerated dose «chemo-switch» regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cance // Clin Oncol. 2005. V. 23. P. 939 – 952.; Combined anti-VEGFR and anti-PDGFR actions of sunitinib on blood vessels in preclinical tumor models / Yao V., Sennino B., Davis R. et al.// Eur J Cancer. 2006. V. 4. P. 27 – 28.; Activity of sunitinib in patients with advanced neuroendocrine tumors / Kulke M., Lenz H., Meropol N. et al. // Clin Oncol. 2008. V. 26. P. 3403 – 3410.; Phase 11 study of sunitinib (SU) in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumors (NET) / Okusaka T., Ito T., Nishida T. et al. // Clin Oncol. 2012. V. 30. P. 381.; Chan J., Kulke M. Targeting the mTOR signaling pathway in neuroendocrine tumors// Curr Treat Options Oncol. 2014. V. 15. N3. P. 365 – 379. doi:10.1007 / s11864‑014‑0294‑4.; Симоненко В. Б., Дулин П. А., Маканин М. А. Возможности таргетной терапии нейроэндокринных опухолей // Клиническая медицина. 2014. Т. 92. № 8. С. 5 – 14.; mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates / O’Reilly K., Rojo F., She Q., Solit D., Mills G., Smith D. et al. // Akt. Cancer Research 66. 2006. P. 1500 – 1508.; A randomized, double-blind, placebo-controlled, multicenter phase III trial of everolimus + octreotide LAR vs placebo + octreotide lar in patients with advanced neuroendocrine tumors (NET) (RADIANT-2) / Pavel M., Hainsworth J., Baudin E. et al. // 35th ESMO Congress. Book of abstracts. 2010. Abstract LBA8.; Everolimus treatment for neuroendocrine tumors: latest results and clinical potential / Pusceddu S., Verzoni E., Prinzi N. et al. // Therapeutic Advances in Medical Oncology. 2017. V. 9. N 3. P. 183 – 188. doi:10.1177 / 1758834016683905.; Everolimus for advanced pancreatic neuroendocrine tumors / Yao J., Shah M., Ito T. et al. // N Engl J Med. 2011. V. 364. P. 514 – 523.; Кузьминов А. Е., Полозкова С. А., Орел Н. Ф., Горбунова В. А. Нейроэндокринные опухоли // Эффективная фармакотерапия. Онкология, гематология и радиология. 2012. N1. С. 44 – 48.; A randomized, double-blind, placebo-controlled, multicenter phase III trial of everolimus in patients with advanced pancreatic neuroendocrine tumors (PNET) (RADIANT-3) / Yao J., Shah M., Ito T. et al. // 35th ESMO Congress. Book of abstracts. 2010. Abstract LBA9.; Jensen R., Delle Fave G. Promising advances in the treatment of malignant pancreatic endocrine tumors // N Engl J Med. 2011. V. 364. P. 564 – 565.; Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study / Yao C., Fazio N., Singh S., Buzzoni R., Carnaghi C., Wolin E. et al. // The Lancet. 5 – 11 March 2016. V. 387. N10022. P. 968 – 977.; Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomised, double-blind, placebocontrolled, phase 3 trial / Pavel M., Singh S., Strosberg J., Bubuteishvili-Pacaud L., Degtyarev E., Neary M. et al. // The Lancet. October 2017. V. 18, N10, P. 1411 – 1422.; Chan J., Kulke M. Progressing in the treatment of neuroendocrine tumors // Curr. Oncol. Rep. 2009. V. 11. P. 193 – 199.; Targeted Systemic Treatment of Neuroendocrine Tumors: Current Options and Future Perspectives / Herrera-Martínez, Aura D et al.// Drugs. 2019. V. 79. N1. P. 21 – 42.; https://www.malignanttumors.org/jour/article/view/685Test

الإتاحة: https://doi.org/10.18027/2224-5057-2019-9-4-49-58Test
https://www.malignanttumors.org/jour/article/view/685Test

المؤلفون: A. Isyangulova Z., R. Khasanov Sh., R. Enikeev F., M. Gordiev G., А. Исянгулова З., Р. Хасанов Ш., Р. Еникеев Ф., М. Гордиев Г.

المصدر: Siberian journal of oncology; Том 18, № 5 (2019); 80-85 ; Сибирский онкологический журнал; Том 18, № 5 (2019); 80-85 ; 2312-3168 ; 1814-4861 ; 10.21294/1814-4861-2019-18-5

مصطلحات موضوعية: pancreatic neuroendocrine tumors, carcinoid tumors, differentiation grade, tumor stage, targeted therapy, somatostatin, нейроэндокринные опухоли поджелудочной железы, карциноид, степень дифференцировки, стадия процесса, таргетная терапия, соматостатин

وصف الملف: application/pdf

العلاقة: https://www.siboncoj.ru/jour/article/view/1193/671Test; Strosberg J.R., Coppola D., Klimstra D.S., Phan A.T., Kulke M.H., Wiseman G.A., Kvols L.K.; North American Neuroendocrine Tumor Society (NANETS). The NANETS consensus guidelines for the diagnosis and management of poorly differentiated (high-grade) extrapulmonary neuroendocrine carcinomas. Pancreas. 2010 Aug; 39(6): 799–800. doi:10.1097/MPA.0b013e3181ebb56f.; Yao J.C., Hassan M., Phan A., Dagohoy C., Leary C., Mares J.E., Abdalla E.K., Fleming J.B., Vauthey J.N., Rashid A., Evans D.B. One hundred years after «carcinoid»: epidemiology of and prognostiс factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008 Jun 20; 26(18): 3063–72. doi:10.1200/JCO.2007.15.4377.; Горбунова В.А. Нейроэндокринные опухоли. Общие принципы диагностики и лечения. М., 2015, 456.; Ramage J.K., Davies A.H., Ardill J., Bax N., Caplin M., Grossman A., Hawkins R., McNicol A.M., Reed N., Sutton R., Thakker R., Aylwin S., Breen D., Britton K., Buchanan K., Corrie P., Gillams A., Lewington V., McCance D., Meeran K., Watkinson A.; UKNETwork for Neuroendocrine Tumours. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours. Gut. 2005 Jun; 54 Suppl 4: iv1–16. doi:10.1136/gut.2004.053314.; Halfdanarson T.R., Rabe K.G., Rubin J., Petersen G.M. Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival. Ann Oncol. 2008 Oct; 19(10): 1727–33. doi:10.1093/annonc/mdn351.; Kim M.K. Neuroendocrine Tumors: A Multidisciplinary Approach. Gastroenterology. 2017; 152(4): 910. doi: https://doi.org/10.1053/j.gastro.2017.01.023Test.; Klimstra D., Arnold R., Capella C. Neuroendocrine neoplasms of the pancreas. WHO Classification of Tumors of the Digestive System. 4th Ed. Lyon: IARC. 2010; 12: 322.; Oberg K. Neuroendocrine gastrointestinal tumors A condensed overview of diagnosis and treatment. Ann Oncol. 1999; 10(2): S3–S8. doi:10.1093/annonc/10.suppl_2.s3.; Симоненко В.Б., Дудин П.А., Маканин М.А. Нейроэндокринные опухоли. М., 2010, 237.; Shkarban V., Nichitaylo M., Scums A. Surgical treatment of malignant nonfunctioning neuroendocrine tumors of the pancreas. Ann Oncol. 2013 June; 24(4): 85. doi:10.1093/annonc/mdt203.170.; Öberg K.U., Knigge D., Kwekkeboom A., Perrenon behalf of the ESMO Guidelines Working Group. Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. 2012; 23(7): 24–30. doi:10.1093/annonc/mds295.; Halfdanarson T.R., Rabe K.G., Rubin J., Petersen G.M. Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival. Ann Oncol. 2008; 19(10): 1727–33. doi:10.1093/annonc/mdn351.; Moertel C.G., Kvols L.K., O’Connell M.J., Rubin J. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin: evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer. 1991; 68: 227–232. doi:10.1002/1097-0142(19910715)68:23.0.co;2-i.; Vilar E., Salazar R., Pérez-García J., Cortes J., Oberg K., Tabernero J. Chemotherapy and role of the proliferation marker ki-67 in digestive neuroendocrine tumors. Endocr Relat Cancer. 2007; 14: 221–232. doi:10.1677/ERC-06-0074.; Childs A., Kirkwood A., Edeline J., Luong T.V., Watkins J., Lamarca A., Alrifai D., Nsiah-Sarbeng P., Gillmore R., Mayer A., Thirlwell C., Sarker D., Valle J.W., Meyer T. Ki-67 index and response to chemotherapy in patients with neuroendocrine tumours. Endocr Relat Cancer. 2016; 563–570. doi:10.1530/ERC-16-0099.; Rinke A., Müller H.H., Schade-Brittinger C., Klose K.J., Barth P., Wied M., Mayer C., Aminossadati B., Pape U.F., Bläker M., Harder J., Arnold C., Gress T., Arnold R.; PROMID Study Group. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009 Oct 1; 27(28): 4656–63. doi:10.1200/JCO.2009.22.8510.; Caplin M.E., Pavel M., Ruszniewski P. Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors. N Engl J Med. 2014 Oct 16; 371(16): 1556–7. doi:10.1056/NEJMc1409757.; Yao J.C., Shah M.H., Ito T. A randomized, double-blind, placebocontrolled, multicenter phase III trial of everolimus in patients with advanced pancreatic neuroendocrine tumors (PNET) (RADIANT-3). 35th ESMO Congress; 2010 Oct 8–12; Milan. LBA9.; Симоненко В.Б., Дулин П.А., Маканин М.А. Возможности таргетной терапии нейроэндокринных опухолей. Клиническая медицина. 2014; 92(8): 5–14.; Wimmel A., Wiedenmann B., Rosewicz S. Autocrine growth inhibition by transforming growth factor beta-1 (TGFbeta-1) in human neuroendocrine tumour cells. Gut. 2003 Sep; 52(9): 1308–16. doi:10.1136/gut.52.9.1308.; von Marschall Z., Scholz A., Cramer T., Schafer G., Schirner M., Oberg K., Wiedenmann B., Hocker M., Rosewicz S. Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis. J Natl Cancer Inst. 2003 Mar 19; 95(6): 437–48. doi:10.1093/jnci/95.6.437.; Chaudhry A., Papanicolaou V., Oberg K., Heldin C.H., Funa K. Expression of platelet-derived growth factor and its receptors in neuroendocrine tumors of the digestive system. Cancer Res.1992; 52: 1006–1012.; Wulbrand U., Remmert G., Zofel P., Wied M., Arnold R., Fehmann H.C. mRNA expression patterns of insulin-like growth factor system components in human neuroendocrine tumours. Eur J Clin Invest. 2000; 30: 729–739.; von Wichert G., Jehle P.M., Hoeflich A., Koschnick S., Dralle H., Wolf E., Wiedenmann B., Boehm B.O., Adler G., Seufferlein T. Insulinlike growth factor-I is an autocrine regulator of chromogranin A secretion and growth in human neuroendocrine tumor cells. Cancer Res. 2000; 60: 4573–4581.; Nilsson O., Wangberg B., Theodorsson E., Skottner A., Ahlman H. Presence of IGF-I in human midgut carcinoid tumours--an autocrine regulator of carcinoid tumour growth? Int J Cancer. 1992; 51: 195203. doi:10.1002/ijc.2910510206.; Zhang H., Yee D. The therapeutic potential of agents targeting the type I insulin-like growth factor receptor. Expert Opin Investig Drugs. 2004 Dec; 13(12): 1569–77. doi:10.1517/13543784.13.12.1569.; Kulke M.H., Lenz H.J., Meropol N.J., Posey J., Ryan D.P., Picus J., Bergsland E., Stuart K., Tye L., Huang X., Li J.Z., Baum C.M., Fuchs C.S. Activity of Sunitinib in Patients With Advanced Neuroendocrine Tumors. J Clin Oncol. 2008 Jul 10; 26(20): 3403–10. doi:10.1200/JCO.2007.15.9020.; Raymond E., Dahan L., Raoul J.L., Bang Y.J., Borbath I., LombardBohas C., Valle J., Metrakos P., Smith D., Vinik A., Chen J.S., Hörsch D., Hammel P., Wiedenmann B., Van Cutsem E., Patyna S., Lu D.R., Blanckmeister C., Chao R., Ruszniewski P. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011 Feb 10; 364(6): 501–13. doi:10.1056/NEJMoa1003825.; Lloyd R.V., Osamura R.Y., Kloppel G., Rosai J. WHO classification of tumours of endocrine organs. 4th edn. Lyon. IARC Press. 2017.; Делекторская В.В. Нейроэндокринные новообразования поджелудочной железы: новые аспекты морфологической классификации (Всемирная организация здравоохранения, 2017). Успехи молекулярной онкологии. 2017; 4(3): 104–108.; Modlin I.M., Gustafsson B.I., Moss S.F., Pavel M., Tsolakis A.V., Kidd M. Chromogranin A – biological function and clinical utility in neuroendocrine tumor disease. Ann Surg Oncol. 2010 Sep; 17(9): 2427–43. doi:10.1245/s10434-010-1006-3.; Моисеенко В.М. Злокачественные опухоли: практические рекомендации по лекарственному лечению злокачественных опухолей (RUSSCO). М., 2017, 656.; https://www.siboncoj.ru/jour/article/view/1193Test

الإتاحة: https://doi.org/10.21294/1814-4861-2019-18-5-80-85Test
https://doi.org/10.21294/1814-4861-2019-18-5Test
https://doi.org/10.1097/MPA.0b013e3181ebb56fTest
https://doi.org/10.1200/JCO.2007.15.4377Test
https://doi.org/10.1136/gut.2004.053314Test
https://doi.org/10.1093/annonc/mdn351Test
https://doi.org/10.1053/j.gastro.2017.01.023Test
https://doi.org/10.1093/annonc/10.suppl_2.s3Test
https://doi.org/10.1093/annonc/mdt203.170Test
https://doi.org/10.1093/annonc/mds295Test

المؤلفون: R. Nurlygayanov, I. Asylbayev, R. Enikeev, R. Yagafarov, I. Minniakhmetov

المصدر: Vestnik Bashkir State Agrarian University. :15-25

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::87967d148723b9fbab2e96c4aaa9e766Test
https://doi.org/10.31563/1684-7628-2022-62-2-15-26Test

المؤلفون: M. A. Petrunin, I. M. Gubaidullin, M. A. Maleeva, N. A. Gladkikh, M. R. Enikeev

المصدر: Protection of Metals and Physical Chemistry of Surfaces. 56:1331-1341

مصطلحات موضوعية: Materials science, 020209 energy, chemistry.chemical_element, 02 engineering and technology, Chloride, Corrosion, law.invention, law, Aluminium, 0202 electrical engineering, electronic engineering, information engineering, Materials Chemistry, medicine, Computer vision, In situ microscopy, business.industry, Organic Chemistry, Metals and Alloys, 021001 nanoscience & nanotechnology, Cathode, Surfaces, Coatings and Films, Anode, chemistry, Scientific method, Hydrogen bubble, Artificial intelligence, 0210 nano-technology, business, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::3a640bdc130e4fc86b17e84ed00e94b6Test
https://doi.org/10.1134/s2070205120070114Test

المؤلفون: R. Enikeev V., Р. Еникеев В.

المصدر: Civil Aviation High Technologies; № 204 (2014); 115-118 ; Научный вестник МГТУ ГА; № 204 (2014); 115-118 ; 2542-0119 ; 2079-0619 ; undefined

مصطلحات موضوعية: MEL, MMEL

وصف الملف: application/pdf

العلاقة: https://avia.mstuca.ru/jour/article/view/597/515Test; Анцелиович Л.Л. Надежность, безопасность и живучесть самолета. - М.: Машиностроение, 1985.; Еникеев Р.В., Прозоров С.Е. Проблемы внедрения системы управления риском в организации по техническому обслуживанию и ремонту // Научный Вестник МГТУ ГА. - 2012. - № 178.; Зубков Б.В., Шаров В.Д. Теория и практика определения рисков в авиапредприятиях при разработке системы управления безопасностью полетов. - М.: МГТУ ГА, 2010.; Doc 7300/9. Конвенция о международной гражданской авиации. - 9-е изд. - Монреаль: ИКАО, 2006.; Кулавский В.Г., Жуков С.А., Шаров В.Д. Разработка системы управления риском с использованием базы данных FleetWatch // Проблемы безопасности полетов. - 2010. - № 3. - С. 14-22.; Махутов Н.А., Петров В.П., Резников Д.О., Куксова В.И. Обеспечение защищенности критически важных объектов на основе снижения их уязвимости // Проблемы безопасности и чрезвычайных ситуаций. - 2009. - № 2. - С. 50-69.; Международные Стандарты и Рекомендуемая практика ИКАО. Приложение 6 к Конвенции о международной гражданской авиации. - Монреаль: ИКАО, 2010. - Ч. I.; Методические указания «О порядке одобрения, контроля и хранения MMEL и MELдля воздушных судов иностранного производства, эксплуатируемых в авиакомпаниях Российской Федерации»30.10.2000 г. №24.9-261.; Правила расследования авиационных происшествий и инцидентов с гражданскими воздушными судами в Российской Федерации (ПРАПИ РФ - 98): утв. постановлением Правительства РФ от 18 июня 1998 г. - № 609.; Прозоров С.Е., Еникеев Р.В. Информационное обеспечение процессов управления безопасностью полётов // Научный Вестник МГТУ ГА. - 2011. - № 174.; Doc 9760-AN/967. Руководство по летной годности. - Т. 1. Организация и процедуры. - 1-е изд. - Монреаль: ИКАО, 2001.; Федеральные авиационные правила «Подготовка и выполнение полетов в гражданской авиации Российской Федерации», Приказ Министерства Транспорта Российской Федерации 31.07.2009 г. № 128.; Шаров В.Д., Еникеев Р.В. Разработка системы управления рисками в организации по техническому обслуживанию и ремонту // Научный Вестник МГТУ ГА. - 2010. - № 162.; http://www.aviasafety.ru/news/nd13032011Test.; http://www.rbcdaily.ru/2012/01/25/industry/562949982608291Test.; http://www.dca.gov.bm/default.aspxTest.; http://www.airlines-inform.ru/commercial-aircraft/Airbus-A320.htmlTest.; Nisula J. Operational Risk Assessment. Next Generation Methodology, 2009. [Электронный ресурс]. URL: http://www.easa.europa.eu/essi/documents/ARMS.pdfTest.; Safety Management Manual (SMM), Second Edition, ICAO, 2009. [Электронный ресурс]. URL: http://www.icao.int/anb/safetymanagementTest/.; Single Aisle Technical Training Manual, Airbus Training and Flight Operation Support anвServices, 2006.; https://avia.mstuca.ru/jour/article/view/597Test; undefined

الإتاحة: https://avia.mstuca.ru/jour/article/view/597Test

المؤلفون: M. A. Maleeva, M. A. Petrunin, N. A. Gladkikh, I. M. Gubaidullin, M. R. Enikeev

المصدر: Corrosion: Materials, Protection. :33-44

مصطلحات موضوعية: In situ, Materials science, Applied Mathematics, Metallurgy, chemistry.chemical_element, Chloride, law.invention, chemistry, Optical microscope, Aluminium, law, Pitting corrosion, medicine, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::78ee69ad97ead9b98e7e72a270b6db06Test
https://doi.org/10.31044/1813-7016-2019-0-12-33-44Test

المؤلفون: N. Agafonova, A. Aleksandrov, O. Altinok, A. Anokhina, S. Aoki, A. Ariga, T. Ariga, D. Autiero, A. Badertscher, A. Bagulya, A. B. Dhahbi, A. Bertolin, M. Besnier, C. Bozza, T. Brugiere, F. Brunet, G. Brunetti, S. Buontempo, A. Cazes, L. Chaussard, M. Chernyavskiy, V. Chiarella, A. Chukanov, N. D'Ambrosio, F. D. Corso, G. D. Lellis, P. D. Sanchez, Y. Declais, M. D. Serio, F. D. Capua, A. D. Crescenzo, D. D. Ferdinando, N. D. Marco, S. Dmitrievski, M. Dracos, D. Duchesneau, S. Dusini, T. Dzhatdoev, J. Ebert, O. Egorov, R. Enikeev, A. Ereditato, L. S. Esposito, J. Favier, T. Ferber, R. A. Fini, D. Frekers, T. Fukuda, G. Giacomelli, M. Giorgini, C. Gollnitz, J. Goldberg, D. Golubkov, L. Goncharova, Y. Gornushkin, G. Grella, F. Grianti, A. M. Guler, C. Gustavino, C. Hagner, K. Hamada, T. Hara, M. Hierholzer, A. Hollnagel, K. Hoshino, M. Ieva, H. Ishida, K. Jakovcic, C. Jollet, F. Juget, M. Kamiscioglu, K. Kazuyama, S. H. Kim, M. Kimura, N. Kitagawa, B. Klicek, J. Knuesel, K. Kodama, M. Komatsu, U. Kose, I. Kreslo, H. Kubota, C. Lazzaro, J. Lenkeit, I. Lippi, A. Ljubicic, A. Longhin, P. Loverre, G. Lutter, A. Malgin, G. Mandrioli, K. Manai, J. Marteau, T. Matsuo, V. Matveev, N. Mauri, F. Meisel, A. Meregaglia, P. Migliozzi, S. Mikado, S. Miyamoto, P. Monacelli, K. Morishima, U. Moser, M. T. Muciaccia, N. Naganawa, T. Naka, M. Nakamura, T. Nakano, D. Naumov, V. Nikitina, K. Niwa, Y. Nonoyama, S. Ogawa, N. Okateva, A. Olshevskiy, M. Paniccia, A. Paoloni, B. D. Park, I. G. Park, A. Pastore, L. Patrizii, E. Pennacchio, H. Pessard, K. Pretzl, V. Pilipenko, C. Pistillo, N. Polukhina, M. Pozzato, F. Pupilli, R. Rescigno, T. Roganova, H. Rokujo, G. Romano, G. Rosa, I. Rostovtseva, A. Rubbia, A. Russo, V. Ryasny, O. Ryazhskaya, O. Sato, Y. Sato, A. Schembri, W. Schmidt Parzefall, H. Schroeder, L. S. Lavina, A. Sheshukov, H. Shibuya, G. Shoziyoev, S. Simone, M. Sioli, G. Sirri, J. S. Song, M. Spinetti, L. Stanco, N. Starkov, M. Stipcevic, T. Strauss, P. Strolin, S. Takahashi, M. Tenti, F. Terranova, I. Tezuka, V. Tioukov, P. Tolun, A. Trabelsi, T. Tran, S. Tufanli, P. Vilain, M. Vladimirov, L. Votano, J. L. Vuilleumier, G. Wilquet, B. Wonsak, V. Yakushev, C. S. Yoon, T. Yoshioka, J. Yoshida, Y. Zaitsev, S. Zemskova, A. Zghiche, R. Zimmermann, BRUGNERA, RICCARDO, GARFAGNINI, ALBERTO, MEDINACELI VILLEGAS, EDUARDO, SIRIGNANO, CHIARA

المساهمون: Agafonova, N., Aleksandrov, A., Altinok, O., Anokhina, A., Aoki, S., Ariga, A., Ariga, T., Autiero, D., Badertscher, A., Bagulya, A., Dhahbi, A. B., Bertolin, A., Besnier, M., Bozza, C., Brugiere, T., Brugnera, Riccardo, Brunet, F., Brunetti, G., Buontempo, S., Cazes, A., Chaussard, L., Chernyavskiy, M., Chiarella, V., Chukanov, A., D'Ambrosio, N., Corso, F. D., Lellis, G. D., Sanchez, P. D., Declais, Y., Serio, M. D., Capua, F. D., Crescenzo, A. D., Ferdinando, D. D., Marco, N. D., Dmitrievski, S., Dracos, M., Duchesneau, D., Dusini, S., Dzhatdoev, T., Ebert, J., Egorov, O., Enikeev, R., Ereditato, A., Esposito, L. S., Favier, J., Ferber, T., Fini, R. A., Frekers, D., Fukuda, T., Garfagnini, Alberto, Giacomelli, G., Giorgini, M., Gollnitz, C., Goldberg, J., Golubkov, D., Goncharova, L., Gornushkin, Y., Grella, G., Grianti, F., Guler, A. M., Gustavino, C., Hagner, C., Hamada, K., Hara, T., Hierholzer, M., Hollnagel, A., Hoshino, K., Ieva, M., Ishida, H., Jakovcic, K., Jollet, C., Juget, F., Kamiscioglu, M., Kazuyama, K., Kim, S. H., Kimura, M., Kitagawa, N., Klicek, B., Knuesel, J., Kodama, K., Komatsu, M., Kose, U., Kreslo, I., Kubota, H., Lazzaro, C., Lenkeit, J., Lippi, I., Ljubicic, A., Longhin, A., Loverre, P., Lutter, G., Malgin, A., Mandrioli, G., Manai, K., Marteau, J., Matsuo, T., Matveev, V., Mauri, N., MEDINACELI VILLEGAS, Eduardo, Meisel, F.

العلاقة: info:eu-repo/semantics/altIdentifier/wos/WOS:000300412700003; volume:14; firstpage:013026; journal:NEW JOURNAL OF PHYSICS; http://hdl.handle.net/11577/2499882Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-84863020093

الإتاحة: https://doi.org/10.1088/1367-2630/14/1/013026Test
http://hdl.handle.net/11577/2499882Test

المؤلفون: F. Milani, Sergey Grigoriev, K. Sapozhnikov, Alexander Roshal, G. Koptelov, R. Enikeev, A. Shilov, Victor Tanchuk, A. Kavin, J. Chiron

المصدر: Fusion Engineering and Design. 124:137-140

مصطلحات موضوعية: Materials science, business.industry, Mechanical Engineering, Nuclear engineering, Plasma, 01 natural sciences, 010305 fluids & plasmas, law.invention, Computer Science::Emerging Technologies, Semiconductor, Nuclear Energy and Engineering, law, Electromagnetic coil, Magnet, 0103 physical sciences, General Materials Science, Resistor, 010306 general physics, business, Energy (signal processing), Circuit breaker, Civil and Structural Engineering, Electronic circuit

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::dbaef1189c3f4a27e33b0bb67824ab82Test
https://doi.org/10.1016/j.fusengdes.2017.02.078Test

المؤلفون: N. Agafonova, A. Aleksandrov, O. Altinok, M. Ambrosio, A. Anokhina, S. Aoki, A. Ariga, T. Ariga, D. Autiero, A. Badertscher, A. Bagulya, A. Bendhabi, A. Bertolin, M. Besnier, D. Bick, V. Boyarkin, C. Bozza, T. Brugiere, F. Brunet, G. Brunetti, S. Buontempo, A. Cazes, L. Chaussard, M. Chernyavsky, V. Chiarella, N. Chon Sen, A. Chukanov, R. Ciesielski, F. D. Corso, N. D'Ambrosio, Y. Declais, P. D. Sanchez, G. D. Lellis, M. D. Serio, F. D. Capua, A. D. Crescenzo, D. D. Ferdinando, N. D. Marco, A. D. Giovanni, S. Dmitrievsky, M. Dracos, D. Duchesneau, S. Dusini, T. Dzhatdoev, J. Ebert, O. Egorov, R. Enikeev, A. Ereditato, L. S. Esposito, J. Favier, T. Ferber, R. A. Fini, D. Frekers, T. Fukuda, V. Galkin, G. Giacomelli, M. Giorgini, J. Goldberg, C. Gollnitz, D. Golubkov, L. Goncharova, Y. Gornushkin, G. Grella, F. Grianti, A. M. Guler, C. Gustavino, C. Hagner, K. Hamada, T. Hara, M. Hierholzer, K. Hoshino, M. Ieva, H. Ishida, K. Ishiguro, K. Jakovcic, C. Jollet, F. Juget, M. Kamiscioglu, J. Kawada, M. Kazuyama, S. H. Kim, M. Kimura, N. Kitagawa, B. Klicek, J. Knuesel, K. Kodama, M. Komatsu, U. Kose, I. Kreslo, H. Kubota, C. Lazzaro, J. Lenkeit, I. Lippi, A. Ljubicic, A. Longhin, G. Lutter, A. Malgin, G. Mandrioli, K. Mannai, A. Marotta, J. Marteau, T. Matsuo, V. Matveev, N. Mauri, E. Medinaceli, F. Meisel, A. Meregaglia, P. Migliozzi, S. Mikado, S. Miyamoto, P. Monacelli, K. Morishima, U. Moser, M. T. Muciaccia, N. Naganawa, T. Naka, M. Nakamura, T. Nakano, Y. Nakatsuka, D. Naumov, V. Nikitina, K. Niwa, Y. Nonoyama, S. Ogawa, A. Olchevsky, T. Omura, G. Orlova, V. Osedlo, M. Paniccia, A. Paoloni, B. D. Park, I. G. Park, A. Pastore, L. Patrizii, E. Pennacchio, H. Pessard, V. Pilipenko, C. Pistillo, N. Polukhina, M. Pozzato, K. Pretzl, P. Publichenko, F. Pupilli, J. P. Repellin, R. Rescigno, T. Roganova, H. Rokujo, G. Romano, G. Rosa, I. Rostovtseva, A. Rubbia, A. Russo, V. Ryasny, O. Ryazhskaya, Y. Sakatani, O. Sato, Y. Sato, A. Schembri, W. Schmidt Parzefall, H. Schroeder, L. S. Lavina, A. Sheshukov, H. Shibuya, S. Simone, M. Sioli, SIRIGNANO, CHIARA, G. Sirri, J. S. Song, M. Spinetti, L. Stanco, N. Starkov, M. Stipcevic, T. Strauss, P. Strolin, K. Suzuki, S. Takahashi, M. Tenti, F. Terranova, I. Tezuka, V. Tioukov, R. Tolun, A. Trabelsi, T. Tran, S. Tufanli, P. Vilain, M. Vladimirov, L. Votano, J. L. Vuilleumier, G. Wilquet, B. Wonsak, V. Yakushev, C. S. Yoon, J. Yoshida, T. Yoshioka, Y. Zaitsev, S. Zemskova, A. Zghiche, R. Zimmermann, BRUGNERA, RICCARDO, GARFAGNINI, ALBERTO

المساهمون: Agafonova, N., Aleksandrov, A., Altinok, O., Ambrosio, M., Anokhina, A., Aoki, S., Ariga, A., Ariga, T., Autiero, D., Badertscher, A., Bagulya, A., Bendhabi, A., Bertolin, A., Besnier, M., Bick, D., Boyarkin, V., Bozza, C., Brugiere, T., Brugnera, Riccardo, Brunet, F., Brunetti, G., Buontempo, S., Cazes, A., Chaussard, L., Chernyavsky, M., Chiarella, V., Chon Sen, N., Chukanov, A., Ciesielski, R., Corso, F. D., D'Ambrosio, N., Declais, Y., Sanchez, P. D., Lellis, G. D., Serio, M. D., Capua, F. D., Crescenzo, A. D., Ferdinando, D. D., Marco, N. D., Giovanni, A. D., Dmitrievsky, S., Dracos, M., Duchesneau, D., Dusini, S., Dzhatdoev, T., Ebert, J., Egorov, O., Enikeev, R., Ereditato, A., Esposito, L. S., Favier, J., Ferber, T., Fini, R. A., Frekers, D., Fukuda, T., Galkin, V., Garfagnini, Alberto, Giacomelli, G., Giorgini, M., Goldberg, J., Gollnitz, C., Golubkov, D., Goncharova, L., Gornushkin, Y., Grella, G., Grianti, F., Guler, A. M., Gustavino, C., Hagner, C., Hamada, K., Hara, T., Hierholzer, M., Hoshino, K., Ieva, M., Ishida, H., Ishiguro, K., Jakovcic, K., Jollet, C., Juget, F., Kamiscioglu, M., Kawada, J., Kazuyama, M., Kim, S. H., Kimura, M., Kitagawa, N., Klicek, B., Knuesel, J., Kodama, K., Komatsu, M., Kose, U., Kreslo, I., Kubota, H., Lazzaro, C., Lenkeit, J., Lippi, I., Ljubicic, A., Longhin, A., Lutter, G., Malgin, A., Mandrioli, G.

العلاقة: info:eu-repo/semantics/altIdentifier/wos/WOS:000280262200004; volume:691; firstpage:138; lastpage:145; numberofpages:7; journal:PHYSICS LETTERS. SECTION B; http://hdl.handle.net/11577/2486217Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-77954623742

الإتاحة: https://doi.org/10.1016/j.physletb.2010.06.022Test
http://hdl.handle.net/11577/2486217Test

المؤلفون: M. A. Maleeva, I. M. Gubaydullin, M. R. Enikeev, Leniza V. Enikeeva, D.I. Potemkin, A. R. Enikeev, Pavel V. Snytnikov

المصدر: Chemical Engineering Journal. 383:123131

مصطلحات موضوعية: Work (thermodynamics), Tafel equation, Materials science, General Chemical Engineering, Kinetics, Thermodynamics, 02 engineering and technology, General Chemistry, 010402 general chemistry, 021001 nanoscience & nanotechnology, 01 natural sciences, Industrial and Manufacturing Engineering, 0104 chemical sciences, Corrosion, Chemical kinetics, Reaction rate constant, Scientific method, Environmental Chemistry, 0210 nano-technology, Dissolution

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::4bfeeafa7b73d2d7a60ac849b2620c12Test
https://doi.org/10.1016/j.cej.2019.123131Test